<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177098</url>
  </required_header>
  <id_info>
    <org_study_id>192024-050</org_study_id>
    <secondary_id>2010-021507-24</secondary_id>
    <nct_id>NCT01177098</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A
      ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once
      daily for 12 weeks in patients with glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 2 at Hour 0, Hour 2 and Hour 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 6 at Hour 0, Hour 2 and Hour 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 12 at Hour 0, Hour 2 and Hour 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8. Average eye IOP is defined as the average of the IOP in both eyes. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">561</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>bimatoprost/timolol formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost/timolol fixed combination ophthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost /timolol formulation A fixed combination ophthalmic solution</intervention_name>
    <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
    <arm_group_label>bimatoprost/timolol formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost/timolol fixed combination ophthalmic solution</intervention_name>
    <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
    <arm_group_label>bimatoprost/timolol fixed combination ophthalmic solution</arm_group_label>
    <other_name>GANFORT®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has ocular hypertension or glaucoma in both eyes

          -  Requires IOP-lowering therapy in each eye

        Exclusion Criteria:

          -  Active or recurrent eye disease that would interfere with interpretation of study data
             in either eye

          -  History of any eye surgery or laser in either eye within 6 months

          -  Required chronic use of other eye medications during the study

          -  Anticipated wearing of contact lenses during the study.

          -  Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <results_first_submitted>February 7, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2013</results_first_posted>
  <last_update_submitted>March 22, 2013</last_update_submitted>
  <last_update_submitted_qc>March 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bimatoprost/Timolol Formulation A</title>
          <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
          <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bimatoprost/Timolol Formulation A</title>
          <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
          <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="278"/>
            <count group_id="B2" value="283"/>
            <count group_id="B3" value="561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" spread="10.61"/>
                    <measurement group_id="B2" value="13" spread="10.82"/>
                    <measurement group_id="B3" value="25" spread="10.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12</title>
        <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Per-protocol population included randomized participants who did not have a protocol violation that significantly affected the conduct or the results of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost/Timolol Formulation A</title>
            <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
            <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12</title>
          <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
          <population>Per-protocol population included randomized participants who did not have a protocol violation that significantly affected the conduct or the results of the trial.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.41" spread="2.232"/>
                    <measurement group_id="O2" value="25.38" spread="2.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_Hour 2 (n=255,260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.79" spread="2.676"/>
                    <measurement group_id="O2" value="24.72" spread="2.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_Hour 8 (n=254,259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.88" spread="3.008"/>
                    <measurement group_id="O2" value="23.82" spread="2.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 0 (n=244,237)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.06" spread="3.216"/>
                    <measurement group_id="O2" value="-8.72" spread="3.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 2 (n=235,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.53" spread="3.520"/>
                    <measurement group_id="O2" value="-8.38" spread="3.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 8 (n=237,234)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.98" spread="3.435"/>
                    <measurement group_id="O2" value="-7.72" spread="3.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2</title>
        <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 2 at Hour 0, Hour 2 and Hour 8.</description>
        <time_frame>Week 2</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost/Timolol Formulation A</title>
            <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
            <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2</title>
          <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 2 at Hour 0, Hour 2 and Hour 8.</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.23" spread="2.746"/>
                    <measurement group_id="O2" value="16.49" spread="2.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2_Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.05" spread="2.877"/>
                    <measurement group_id="O2" value="16.23" spread="2.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2_Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.49" spread="2.596"/>
                    <measurement group_id="O2" value="15.83" spread="2.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12</title>
        <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost/Timolol Formulation A</title>
            <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
            <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Worse Eye IOP at Each Hour Evaluated at Week 12</title>
          <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8 in the worse eye, defined as the eye with the worse (higher) IOP at baseline. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.34" spread="2.233"/>
                    <measurement group_id="O2" value="25.30" spread="2.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.71" spread="2.700"/>
                    <measurement group_id="O2" value="24.61" spread="2.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.81" spread="2.989"/>
                    <measurement group_id="O2" value="23.80" spread="2.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.94" spread="3.290"/>
                    <measurement group_id="O2" value="-8.51" spread="3.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.44" spread="3.646"/>
                    <measurement group_id="O2" value="-8.08" spread="3.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.87" spread="3.496"/>
                    <measurement group_id="O2" value="-7.52" spread="3.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12</title>
        <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8. Average eye IOP is defined as the average of the IOP in both eyes. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost/Timolol Formulation A</title>
            <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
            <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Eye IOP at Each Hour Evaluated at Week 12</title>
          <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP was evaluated at Baseline and Week 12 at Hour 0, Hour 2 and Hour 8. Average eye IOP is defined as the average of the IOP in both eyes. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.94" spread="2.116"/>
                    <measurement group_id="O2" value="24.86" spread="2.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.29" spread="2.515"/>
                    <measurement group_id="O2" value="24.23" spread="2.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.42" spread="2.904"/>
                    <measurement group_id="O2" value="23.36" spread="2.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.65" spread="3.109"/>
                    <measurement group_id="O2" value="-8.30" spread="3.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.11" spread="3.392"/>
                    <measurement group_id="O2" value="-7.86" spread="3.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12_Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="3.395"/>
                    <measurement group_id="O2" value="-7.27" spread="3.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6</title>
        <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 6 at Hour 0, Hour 2 and Hour 8.</description>
        <time_frame>Week 6</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost/Timolol Formulation A</title>
            <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
            <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6</title>
          <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 6 at Hour 0, Hour 2 and Hour 8.</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.28" spread="2.754"/>
                    <measurement group_id="O2" value="16.31" spread="2.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6_Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.90" spread="2.910"/>
                    <measurement group_id="O2" value="16.17" spread="2.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6_Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.71" spread="2.755"/>
                    <measurement group_id="O2" value="15.82" spread="2.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12</title>
        <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 12 at Hour 0, Hour 2 and Hour 8.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost/Timolol Formulation A</title>
            <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
            <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12</title>
          <description>Intraocular pressure (IOP) is a measurement of the fluid pressure inside the eye. Average eye IOP is the average IOP of both eyes and was evaluated at Week 12 at Hour 0, Hour 2 and Hour 8.</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12_Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.29" spread="2.783"/>
                    <measurement group_id="O2" value="16.56" spread="2.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12_Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.18" spread="2.845"/>
                    <measurement group_id="O2" value="16.37" spread="2.699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12_Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.85" spread="2.786"/>
                    <measurement group_id="O2" value="16.09" spread="2.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population (all treated participants) was used to calculate the number of participants at risk for Serious Adverse Events and Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bimatoprost/Timolol Formulation A</title>
          <description>One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Bimatoprost/Timolol Fixed Combination Ophthalmic Solution</title>
          <description>One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

